

06990.1




FIG. 1

06990.1




FIG. 2

Table 1
Pharmacy Risk Groups

PRG	Description	PRG	Description
01	Anti-Infectives	04	Cardiovascular (CV)
01.01	Amebicides and Antifungal Antibiotics	04.01	Beta Adrenergic Antagonists, Alpha 1-Adrenergic Antagonists
01.02	Aminoglycosides excluding Cystic Fibrosis Agents	04.02	Carvedilol, Nitrates and Nitrites, Digoxin
01.03	Arthritis Agents	04.03	Antihypertensive Agents
01.04	Antituberculosis Agents	04.04	Antiarrhythmic Agents
01.05	Cephalosporins, Macrolides, other Selected Anti-Infective Agents	04.05	Other Cardiovascular Agents, NEC
01.06	HIV Antiviral Agents	04.06	Calcium Channel Antagonists
01.07	Leprostatics	04.07	Vasodilating Agents
01.08	Miscellaneous Antibiotics, NEC	04.08	Vasopressors used in Shock, Midodrine HCL
01.09	Non-HIV Antiviral Agents, NEC	04.81*	Higher Risk CAD, Anti-Infectives/Antibiotics Comorbidity
01.10	Quinolones	04.82*	Higher Risk CAD, CNS Comorbidity
01.11	Higher Cost Anti-Infectives, NEC	04.83*	Higher Risk CAD, GI Comorbidity
01.81*	Multiple Selected Anti-Infective Agents, I	04.84*	Higher Risk CAD, Insulin Comorbidity
01.82*	Multiple Selected Anti-Infective Agents, II	04.85*	Higher Risk CAD, Respiratory Comorbidity
02	Antineoplastics	04.86*	Mod/Lower Risk CAD/Hypertension, GI Comorbidity
02.01	Antineoplastics, I (Nitrogen Mustards, Nitrosureas, Anthracycline Antibiotics)	04.87*	Mod/Lower Risk CAD/Hypertension, Insulin Comorbidity
02.02	Antineoplastics, II (Androgens/Anti-Androgens for Chemotherapeutic Use)	04.88*	Mod/Lower Risk CAD/Hypertension, Respiratory Comorbidity
02.03	Antineoplastics, III (Antimetabolites and Selected Chemotherapy Agents)	04.89*	Loop and Higher Risk Diuretics Comorbidity
02.04	Antineoplastics, IV (Gonadotropin-Releasing Hormones for Chemotherapy)	04.90*	Higher Risk CAD, 3 or more Comorbid
02.05	Antineoplastics, V (Miscellaneous Antineoplastics, NEC)	05	Central Nervous System (CNS)
02.06	Antineoplastics, VI (Hepatitis Agents)	05.01	Migraine Agents and Selected Salicylates
02.07	Antineoplastics, VII (Agents used to treat Breast Cancer, I)	05.02	Agents used to treat Alzheimer's Disease
02.08	Antineoplastics, VII (Agents used to treat Breast Cancer, II)	05.03	Agents used to treat Multiple Sclerosis
03	Blood Formation and Modification	05.04	Agents used to treat ALS
03.01	Antithrombotic Agents	05.05	Agents used to treat Parkinson Disease
03.02	Anticoagulants - Antiplatelets, Coumarin, Heparins, Glycosaminoglycans	05.06	Amphetamines and Miscellaneous CNS Stimulants, NEC
03.03	Folic Acid-Folinic Acid Products	05.07	Anorexiant
03.04	Hematopoietic Agents	05.08	Antiemetic Agents used in treatment of Cancer
03.05	Iron and Iron Combinations	05.09*	Antiemetic Agents, NEC, > 18 years of age
03.06	Hemostatics and Thrombolytic Enzymes	05.10	Antipsychotic and Antimanic Agents
03.07	Vitamin B12 and K Products	05.11	Antivertigo Agents-Anticholinergics

FIG. 3a

Table 1 (continued)
Pharmacy Risk Groups

PRG	Description	PRG	Description
05	Central Nervous System (CNS), Continued	09	Hormones and Synthetic Agents
05.12	Barbiturate General Anesthetics and Sedative Hypnotics	09.01	Antidiabetic Agents, excluding Insulin
05.13	Antidepressants, Antianxiety Agents, Nonbarbiturate Sedative Hypnotics, NEC	09.02	Antithyroid Agents and Thyroid Hormones
05.14	Narcotic Agonist Analgesics and Agonist-Antagonist Combinations	09.03	Bone Resorption Inhibitors, Agents associated w treatment of Osteoporosis
05.15	Centrally Acting Analgesics, Muscle Relaxants and Narcotic Analgesic	09.04	Estrogens, Progestins, Oxytocics
05.16	Other CNS Agents, NEC	09.05*	Glucocorticoids, > 18 years of age
05.17	Anticonvulsants	09.06*	Glucocorticoids, 0-18 years of age
05.18	Selected Skeletal Muscle Relaxants, used in treatment of Multiple Sclerosis	09.07	Growth Hormones
05.19	Narcotic Agonist Analgesics, Higher Risk	09.08	Ovulation Stimulants
05.81*	Antipsychotic/Anti-Manic with Antidepressant/Antianxiety Agents	09.09	Anabolic Steroids
05.82*	Higher Risk Narcotic Agonist Analgesics with other Analgesic Agents	09.10	Insulin
05.83*	Selected CNS Agents, Single, with Antidepressant/Antianxiety	09.11	Vasopressin Derivatives and other selected Hormones/Synthetic Substitutes
05.84*	Selected CNS Agents, Multiple, with Antidepressant/Antianxiety	09.12	Natural and Synthetic Androgens
05.85*	Antiemetics used in treatment of Cancer, w evidence of Antineoplasics	09.81*	Insulin, Anti-Infectives/Antibiotics Comorbidity
07	Electrolyte/Caloric/Water Balance	09.82*	Insulin, CNS Agents Comorbidity
07.01	Acidifying Agents, Alkanalyzing Agents	09.83*	Insulin, Gastrointestinal Agents Comorbidity
07.02	Agents used to treat Electrolyte Disorders, Ion Exchange Resins	09.84*	Non-Insulin Diabetes, Anti-Infectives/Antibiotics Comorbidity
07.03	Ammonia Detoxicants	09.85*	Non-Insulin Diabetes, CNS Agents Comorbidity
07.04	Carbonic Anhydrase Inhibitors	09.86*	Insulin, 3 or more Comorbidities
07.05	Diuretics and Thiazides, excl Loop and Higher Risk Diuretics, > 18 yrs of age	09.87*	Non-Insulin Diabetes, 3 or more Comorbidities
07.06	Diuretics and Thiazides, excl Loop and Higher Risk Diuretics, 0-18 yrs of age	10	Nutritional Agents
07.07	Loop Diuretics	10.01	B Vitamins and Derivatives
07.08	Higher Risk Diuretics	10.02	Calcium Supplements-Oral
08	Gastrointestinal Agents (GI)	10.03	Prenatal - Vitamins / Minerals / Combination Products
08.01	Agents used to treat Inflammatory Bowel Disease	10.04	Nutritional Supplements for Deficiency States and Vitamin D Analogs
08.02	Antidiarrheal/Antiflatulent Agents		
08.03	Antacids, Anticholinergics and other Selected GI Agents, NEC, > 18 yrs of age		
08.04	Gastrointestinal Prokinetic Agents		
08.05	GI Agents, NEC		
08.06	Proton Pump Inhibitors		
08.81*	Selected GI Agents with 0-18 years of age		

Table 1 (continued)
Pharmacy Risk Groups

PRG	Description	PRG	Description
11	R spiratory	Other Agents	
11.01	Inhaled Corticosteroids	12.01	Higher Cost Immunologic Agents
11.02	Antihistamines	12.02	Agents for Xerostomia
11.03	Leukotriene Receptor Antagonists	15.01	Oral Antifungals
11.04	Xanthine-Sympathomimetics and other selected Respiratory Agents	17.01	Agents to Treat Impotence
11.05	Xanthine Derivatives	17.02	Cholinergic Muscle Stimulants
11.06	Inhaled Anticholinergic Agents	17.03	Urinary Anticholinergics
11.81*	Inhaled Anticholinergic Agents with other Respiratory Agents	17.04	Narcotic Antagonist Antidotes
11.82*	Respiratory, 3 Comorbidities	17.05	Chelating Antidotes - Penicillamin, Trientine
13	Topical Ophthalmic Preparations	17.06	Agents to Treat Enzyme Deficiency States
13.01	Ophthalmic Antihistamines, Anti-Allergy and Non-Steroidal Anti-Inflammatories	30.01	Agents to Treat Cystic Fibrosis, I
13.02	Agents to Treat Glaucoma	30.02	Agents to Treat Cystic Fibrosis, II
13.03	Cycloplegic Mydriatics		
13.04	Ophthalmic Anti-Infectives and Corticosteroids		
16	Topical Skin and Mucous Membranes		
16.01	Miscellaneous Topical Skin and Mucous Membrane Agents		
16.02	Topical Corticosteroids		
16.03	Topical Enzymes and Combinations		
16.04	Topical Skin and Mucus Membrane Anesthetics		
16.05	Topical Wound Healing Agents		

Note: An asterisk (*) indicates an added PRG or an initial PRG modified by additional logic.

FIG. 3c

Table 2
Examples of PRG Risk Score Assignment

Example 1
Male, Age 58

DCC	Description	PRG	Description	Risk Weight
01500	Ciprofloxacin HCL / Lactate IV	01.10	Quinolones	0.3495
25605	Lisinopril	04.03	Antihypertensive Agents	0.2819
00600	Erythromicin	01.05	Cephalosporins, Macrolides, and other Selected Anti-Infective Agents	0.0925
32000	Fluoxetine HCL	05.13	Antidepressants, Antianxiety Agents and Nonbarbituate Sedative Hypnotics, NEC	0.4729
32001	Sertraline	05.13	Antidepressants, Antianxiety Agents and Nonbarbituate Sedative Hypnotics, NEC	0.0000
30302	Ibuprofen	-----	Not assigned to a PRG	0.0000
Age-Sex Male, 58		Age-Sex Group Males, 55 to 64		1.0219
Total Risk Score				2.2187

Example 2
Male, Age 58

DCC	Description	PRG	Description	Risk Weight
58201	Flunisolide	11.02	Antihistamines	0.1195
24901	Carvedilol	04.02	Carvedilol, Nitrates and Nitrites, Digoxin	0.3131
50401	Insulin	09.10	Insulin	1.0682
	Co-morbid PRG	04.84	Higher Risk CAD, Insulin Comorbidity	1.2375
Age-Sex		Age-Sex Group		
	Male, 58		Males, 55 to 64	1.0219
Total Risk Score				3.7602

Example 3
Female, Age 52

DCC	Description	PRG	Description	Risk Weight
34604	Riluzole	05.04	Agents to treat ALS	12.0071
32000	Fluoxetine HCL	05.13	Antidepressants, Antianxiety Agents and Nonbarbiturate Sedative Hypnotics, NEC	0.4729
Age-Sex Female, 52		Age-Sex Group Females, 45 to 54		0.6650
T tal Risk Scor				13.1450

FIG. 4